StockData
Agentix Corp. logo

Agentix Corp. (AGTX) stock

AGTXOTCBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 0/30
$0.02+0.00 (0.00%)

Close on Oct 16, 2026Market cap $801.34KP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$801.34K
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$417.49K
EPS, diluted
$0.00
Book value per share
-$0.09
Diluted shares
40M

Trading

Previous close
$0.02
Open
$0.02
Day's range
$0.02 – $0.02
Volume
0

Market cap history

Month-end market cap since 2015, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodAGTXS&P 500DifferenceAGTX per yearS&P 500 per year
1 month0.0%+1.5%−1.5 pts
3 months0.0%+1.9%−1.9 pts
Year to date-46.7%+12.8%−59.5 pts
1 year-59.9%+16.8%−76.7 pts
3 years-71.8%+81.5%−153.3 pts-34.4%+22.0%
5 years-97.5%+83.0%−180.5 pts-52.2%+12.8%
10 years-99.9%+319.4%−419.3 pts-51.0%+15.4%

Twelve years at a glance

Fiscal years 2013 to 2026 and trailing twelve months, USD

Revenue

–

Gross profit

–

Operating income

-$340.35K

Net income

-$417.49K

EPS, diluted

$0.00

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Agentix filed with the SEC as exhibits to Form 8-K or 6-K

About Agentix

Biological Products, (No Diagnostic Substances)

Agentix Corp. is a clinical-stage biopharmaceutical company that focuses on developing treatments for metabolic disorders, including type 2 diabetes, obesity, and fatty liver disease. The company's therapeutic pipeline centers on peripherally-restricted cannabinoid type 1 receptor antagonists and inverse agonists designed not to cross the blood-brain barrier. Its primary product candidates include AGTX-2004, a CB1 receptor antagonist advancing toward human clinical trials, and AGTX-2003, an inverse agonist undergoing preclinical evaluation. Because its drug candidates remain in development without commercial sales, the firm has no commercial customers, though it aims to partner with larger pharmaceutical corporations.

Company profile, executives and history

Agentix stock: common questions

What is Agentix's stock price?

AGTX closed at $0.02 on Oct 16, 2026, up 0.00% on the day.

What is Agentix's market cap?

Agentix was worth $801.34K at the close on Oct 16, 2026: the share price times the diluted shares outstanding.

What is AGTX's P/E ratio?

Agentix lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.

Does Agentix pay a dividend?

No. Agentix has not paid a cash dividend over the last twelve months.

How has AGTX stock performed over the past year?

Including dividends, AGTX returned -59.9% over the past year, against +16.8% for the S&P 500.

Who are Agentix's competitors?

Companies most similar to Agentix by business, industry and size include OKYO, KLRS, ELOX, NMRA, MAZE.

See a number that looks wrong?